Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

2(100.0%)

2Total

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT05721235Phase 4Completed

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Role: collaborator

NCT05685732Phase 4Completed

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Role: collaborator

NCT05438485Terminated

Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia

Role: collaborator

NCT01535664Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Role: collaborator

All 4 trials loaded